Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: An open multi-drug comparison trial

Hellenic Journal of Cardiology

Volumn 47, Issue 1, 2006, Pages 21-28

  Kyvelou, Stella Maria G ^a,b   Vyssoulis, Gregory P ^a   Karpanou, Eva A ^a   Adamopoulos, Dionysios N ^a   Zervoudaki, Alexandra I ^a   Pietri, Panagiota G ^a   Stefanadis, Christodoulos I ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Angiotensin II; Angiotensin receptor blockers; Hypertension; Lipid profile; Metabolic effect

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CANDESARTAN; CHOLESTEROL; EPROSARTAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRBESARTAN; LIPID; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ACRYLATES; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LIFE STYLE; LIPOPROTEINS; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES; THIOPHENES; VALINE;

EID: 33645538850     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kannel WB: Hypertension as a risk factor for cardiac events: epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993; 21: 27-37.
2. Fedder DO, Koro CE, L'Italien GJ: New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid - Lowering Drug Therapy. Circulation 2002; 105: 152-156.
3. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Meredith PA: Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs 2005; 5: 171-183.
5. Ran J, Hirano T, Adachi M: Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 2: 227-232.
6. Benson C, Pershadsingh H, Ho C, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43:993.
7. Lerch M, Teuscher A, Beissner P: Effects of angiotensin II receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J C Pharm 1998; 31: 576-580.
8. Derosa G, Ragonesi PD, Mugellini A, et al: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457-464.
9. Hanefeld M, Abletshauser C: Effect of angiotensin receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29: 270-279.
10. Seventh report of the Joint National Committee on prevention, detection, evaluation, treatment of high blood pressure. Hypertension. 2003; 42: 1206-1252.
11. Catena C, Novello M, Lapenna R, et al: New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein (a). J Hypertens 2005; 23: 1617-1631.
12. Kwiterovich PO: The antiatherogenetic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: 13-21.
13. American Association of Clinical Endocrinologists: AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 2000; 62: 162-213.
14. Prisant LM: Preventing type II diabetes mellitus. J Clin Pharmacol 2004; 44: 406-413.
15. Keidar S, Kaplan M, Hoffman A, et al: Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-215.
16. Nickening G, Jung O, Strehlow K, et al: Hypercholesterolemia is associated with enhanced angiotensin AT1 receptor expression. Am J Physiol 1997; 272: 2701-2707.
17. Nickenig G, Baumer AT, Temur Y, et al: Dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
18. Markham A, Spencer CM, Jarvis B: Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000; 59: 1187-1206.
19. Walczak R, Tontonoz P: PPARadigms and PPARadoxes expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002; 43: 177-186.